Global Fungal Infections Market is estimated to be US$ 2.52 billion by 2030 with a CAGR of 3.0% duri (Business Opportunities - Marketing & Sales)

USAOnlineClassifieds > Business Opportunities > Marketing & Sales

Item ID 1535816 in Category: Business Opportunities - Marketing & Sales

Global Fungal Infections Market is estimated to be US$ 2.52 billion by 2030 with a CAGR of 3.0% duri

Global Fungal Infections Market accounted for US$ 1.98 billion in 2020 and is estimated to be US$ 2.52 billion by 2030 and is anticipated to register a CAGR of 3.0%.Pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis (thrush), serious systemic infections such as cryptococcal meningitis, and others is known as an antifungal medicine, sometimes known as an antimycotic medication. The majority of these medications require a doctor's prescription, although a handful are available over the counter (OTC). Antifungals are divided into two categories: local and systemic. Depending on the problem being treated, local antifungals are commonly used topically or vaginally. Antifungals for the system are taken orally or intravenously. Only a few azole antifungals are utilised systemically in clinical practise.

The report " Global Fungal Infections Market, By Drug Type (Echinocandins {Caspofungin, Micafungin, Anidulafungin, and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles, and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin, Natamycin, and Others}, Allylamines {Butenafine, Terbinafine, and Naftifine}, and Others), By Infection Type (Superficial Antifungal Infection and Systemic Antifungal Infection), By Dosage form (Drugs, Ointment, Powder, and Others), By Therapeutic Indication (Aspergillosis, Dermatophytosis, Candidiasis, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

In 2021, Posaconazole, a novel triazole antifungal medicine from Cadila Pharmaceuticals, is effective against a wide spectrum of invasive fungal illnesses. The medicine has also been suggested as a second-line treatment for Mucormycosis, also known as black fungus.
In 2021, Posaconazole API was launched by Bajaj Healthcare to treat Mucormycosis (black fungus) infection in COVID-19 patients.
Analyst View:

The rising occurrence of fungal diseases around the world is fueling the market's expansion. Furthermore, increased use of immunosuppressive and antineoplastic drugs, prosthetic devices and grafts, and broad-spectrum antibiotics has led in an upsurge in fungal infections in recent years. According to statistics provided by the Centers for Disease Control and Prevention in 2017, over 220,000 new people are infected with cryptococcal meningitis each year, which is a brain infection that causes 181,000 deaths each year around the world. Because of the high incidence of HIV/AIDS in Sub-Saharan Africa, the majority of the deaths were reported there. Due to the significant prevalence of mycological diseases over the world, this indicates a potential market for antifungal medications. The expansion in the global geriatric population is projected to increase demand for antifungals to treat opportunistic fungal infections, as older people are more susceptible to infectious diseases and chronic disorders, such as HIV and cancer. The demand for fungistatic drugs is expected to continue robust through 2025, owing to an increase in cases of difficult-to-diagnose fungal infections that result in high mortality and morbidity rates.

To know the upcoming trends and insights prevalent in this market, click the link below:

Related Link: Click here to visit item owner's website (0 hit)

Target State: All States
Target City : All Cities
Last Update : Oct 27, 2021 1:58 AM
Number of Views: 51
Item  Owner  : NileshDM
Contact Email:
Contact Phone: 7775049802

Friendly reminder: Click here to read some tips.
USAOnlineClassifieds > Business Opportunities > Marketing & Sales
 © 2022
2022-06-26 (0.402 sec)